Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: J Thromb Haemost. 2015 Apr 23;13(6):1064–1072. doi: 10.1111/jth.12901

Fig. 1.

Fig. 1

Bilirubin inhibits proteolytic cleavage of fluorogenic substrates by ADAMTS13 that is reversible by treatment with bilirubin oxidase. A. Constructs expressing rVWF73 contained Cys substitution at Q1599 and N1610 for labeling and a C-terminal 6xHis epitope and GST-rVWF71-11K peptide. B. Inhibition of plasma ADAMTS13 activity by unconjugated bilirubin at various concentrations (0-125 μM, final), assayed by the cleavage of F485-rVWF73-H or D633-rVWF73-H as indicated. The relative activity (%) is expressed as the means ± standard errors from three independent experiments. C. Inhibition of plasma ADAMTS13 activity by unconjugated bilirubin assayed by the cleavage of GST-rVWF71-11K using SELDI-TOF-MS. D. Bilirubin oxidase reverses the inhibitory activity of unconjugated bilirubin on the cleavage of D633-rVWF73-H by plasma ADAMTS13. The data represent the means ± standard errors from three independent experiments.